ASCIERTO , Paolo A.

Last name: ASCIERTO

First name: Paolo A.

March 11, 2024 (v1)

Publication

Metadata-only

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma

Dreno, Brigitte Ascierto, Paolo A. Atkinson, Victoria

Background: In the coBRIM study, cobimetinib plus vemurafenib (C þ V) significantly improved survival outcomes vs placebo and vemurafenib (P þ V) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life (HRQOL) from coBRIM is reported. Methods: Patients completing the European Organisation...

Uploaded on: March 13, 2024
March 5, 2024 (v1)

Publication

Metadata-only

Adjuvant pembrolizumab versus placebo in resected high risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

Khattak, Muhammad A. Luke, Jason J. Long, Georgina V.

Abstract Background: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. Methods: Patients were randomly assigned 1:1 to pembrolizumab 200 mg (2 mg/kg, patients 12 to <18...

Uploaded on: March 7, 2024
2018 (v1)

Publication

Metadata-only

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Queirolo, Paola Dozin, Beatrice Morabito, Anna

No description

Uploaded on: April 14, 2023

ASCIERTO , Paolo A.

Recent uploads